Welcome to our dedicated page for Aurora Cannabis SEC filings (Ticker: ACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
Aurora Cannabis Inc. reported fiscal Q3 2026 results showing continued strength in its global medical cannabis franchise and solid cash generation. Total net revenue was $94.2 million, up 7% year over year, driven by a record $76.2 million in medical cannabis net revenue, which supplied most of the company’s sales and adjusted gross profit.
Consolidated adjusted gross margin before fair value adjustments was 62%, while adjusted EBITDA was $18.5 million, slightly below the prior year but up sequentially. Free cash flow reached $15.5 million, reflecting better operating cash and modest maintenance capex. Adjusted net income was steady at $7.2 million.
The company plans to exit selected lower-margin Canadian consumer markets starting Q4 FY26 to focus further on higher-margin medical cannabis, expecting lower adjusted SG&A and better margins after some one-time Q4 costs. Aurora also agreed to restructure its Bevo Agtech investment into preferred shares with a 5% dividend and a share of Bevo cash flows, after which Bevo will be deconsolidated and treated as a discontinued operation. In parallel, Aurora established a new at-the-market equity program allowing issuance of up to US$100 million of common shares from treasury for strategic and accretive uses such as added cultivation capacity and potential M&A.
Aurora Cannabis Inc. reported fiscal Q3 2026 results showing continued strength in its global medical cannabis franchise and solid cash generation. Total net revenue was $94.2 million, up 7% year over year, driven by a record $76.2 million in medical cannabis net revenue, which supplied most of the company’s sales and adjusted gross profit.
Consolidated adjusted gross margin before fair value adjustments was 62%, while adjusted EBITDA was $18.5 million, slightly below the prior year but up sequentially. Free cash flow reached $15.5 million, reflecting better operating cash and modest maintenance capex. Adjusted net income was steady at $7.2 million.
The company plans to exit selected lower-margin Canadian consumer markets starting Q4 FY26 to focus further on higher-margin medical cannabis, expecting lower adjusted SG&A and better margins after some one-time Q4 costs. Aurora also agreed to restructure its Bevo Agtech investment into preferred shares with a 5% dividend and a share of Bevo cash flows, after which Bevo will be deconsolidated and treated as a discontinued operation. In parallel, Aurora established a new at-the-market equity program allowing issuance of up to US$100 million of common shares from treasury for strategic and accretive uses such as added cultivation capacity and potential M&A.
Aurora Cannabis Inc. reports interim results for the three and nine months ended December 31, 2025, showing modest revenue growth but continued losses and restructuring. Net revenue reached C$94.2 million for the quarter and C$282.6 million year-to-date, driven mainly by medical cannabis sales in Europe and Canada plus U.S. plant propagation.
The company posted a quarterly net loss of C$1.9 million and a nine‑month net loss of C$74.8 million, reflecting inventory provisions, fair value adjustments on biological assets and a C$31.9 million impairment of goodwill and intangibles tied to Australian cannabis and plant propagation. Total assets declined to C$775.3 million and shareholders’ equity to C$567.8 million.
Bevo’s credit facility covenants were breached, causing C$61.8 million of loans and borrowings to be classified as current. Subsequent events include a new at‑the‑market equity program for up to US$100 million of common shares, a decision to exit certain lower‑margin Canadian consumer markets, and an agreement to exchange Aurora’s Bevo common shares for preferred shares, after which Bevo will be deconsolidated and reported as a discontinued operation.
Aurora Cannabis Inc. reports interim results for the three and nine months ended December 31, 2025, showing modest revenue growth but continued losses and restructuring. Net revenue reached C$94.2 million for the quarter and C$282.6 million year-to-date, driven mainly by medical cannabis sales in Europe and Canada plus U.S. plant propagation.
The company posted a quarterly net loss of C$1.9 million and a nine‑month net loss of C$74.8 million, reflecting inventory provisions, fair value adjustments on biological assets and a C$31.9 million impairment of goodwill and intangibles tied to Australian cannabis and plant propagation. Total assets declined to C$775.3 million and shareholders’ equity to C$567.8 million.
Bevo’s credit facility covenants were breached, causing C$61.8 million of loans and borrowings to be classified as current. Subsequent events include a new at‑the‑market equity program for up to US$100 million of common shares, a decision to exit certain lower‑margin Canadian consumer markets, and an agreement to exchange Aurora’s Bevo common shares for preferred shares, after which Bevo will be deconsolidated and reported as a discontinued operation.
Aurora Cannabis Inc. filed a Form 6-K to share a news release announcing the schedule for its fiscal third quarter 2026 financial results and investor conference call. The company plans to release its Q3 2026 results before markets open on Wednesday, February 4, 2026, followed by a conference call at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time) that same day.
The call will be hosted by Executive Chairman and Chief Executive Officer Miguel Martin and Chief Financial Officer Simona King, and will include a question-and-answer period. Aurora describes itself as a Canadian-based global medical and consumer cannabis company with operations across Canada, Europe, Australia and South America, with brands spanning adult-use and medical markets and a controlling interest in Bevo Farms Ltd.
Aurora Cannabis Inc. reports significant progress in its research on powdery mildew-resistant cannabis, known as PM2, in this Form 6-K. The company has moved from lab work to production trials of cultivars with verified PM2 resistance at its Aurora Ridge facility, using controlled infection tests to confirm disease resistance while maintaining high-quality traits for patients and consumers.
Aurora has presented this work at several scientific conferences and notes that the PM2 marker technology, developed at its Aurora Coast R&D center with academic and funding partners, is patent pending in Canada, the United States, Europe, Australia, New Zealand and Israel. If production trials succeed, Aurora plans to commercialize powdery mildew-resistant cultivars later this year, aiming to protect plant health, reduce operational costs and improve product quality across its global medical cannabis portfolio.